Analysis: FDA's new guidance for digital therapeutics

Issue 048.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 59 percent open rate. Here's what's happening this week:

As part of the effort to make virtual care more accessible during the COVID--19 pandemic, the FDA posted a new enforcement guidance focused on digital health devices for the treatment of psychiatric disorders. Given how many DTx companies are focused on behavioral health, this move by the FDA has a lot of companies re-examining their go-to-market timeline. I pushed back the MSK report a few days as I've been on the phone with readers non-stop trying to getting my head around this guidance. Read more on the FDA's in today's top story below...
Decisions Resources Group has a worthwhile report out on payers' perspectives around digital therapeutics that is based on responses from 157 P&T committee members at

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Analysis: FDA’s new guidance for digital therapeutics

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

Analysis: FDA’s new guidance for digital therapeutics

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.